‘Bigger than just Covid vaccines’: US drug giant Moderna wants to collaborate with Hong Kong scientists on mRNA technology with local branch

• Patrick Bergstedt, Moderna senior vice-president and head of emerging markets, says city subsidiary will focus on engaging local stakeholders, with eventual goal to tap into Greater Bay Area
• He hails Hong Kong’s established network, excellent healthcare system and academic circles as pull factors for company